We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 02, 2020

Preemptive TKI Strategy for Preventing Relapse Based on BCR/ABL Monitoring in Patients With Ph+ ALL Undergoing Allo-HCT



Additional Info

Disclosure statements are available on the authors' profiles:

A New Pre-Emptive TKIs Strategy for Preventing Relapse Based on BCR/ABL Monitoring for Ph+ ALL Undergoing Allo-HCT: A Prospective Clinical Cohort Study
Leukemia 2020 Nov 17;[EPub Ahead of Print], H Liu, L Xuan, R Lin, L Deng, Z Fan, D Nie, X Li, X Liang, D Xu, Y Zhang, N Xu, J Ye, H Jin, D Lin, L Ma, J Sun, F Huang, Q Liu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading